Lipocine Inc LPCN 2.2%’s LPCN-1021’s PDUFA date is coming up on June 28. Given the major potential near-term catalyst, Slingshot Insights recently conducted an expert conference call with a professor, researcher and a clinical director from the Department of Medicine at Johns Hopkins University on June 9 to allow investors the chance to ask questions about the oral male hypogonadism drug. Here are some highlights from the call.

In terms of market penetration, the expert told callers, “There is a need for an oral medication. I think it’s going to take a big chunk of the market if it gets approved.”

The doctor said Americans will prefer the pill to the topical creams that are out there in the market already, but the problem will be price.

“Patients will want the pill, but the problem might be due to the insurance companies, patients who are not going to pay for this expensive pill, when you can get generic gel that’s already on the market,” he said.

The doctor also discussed…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!